Iterum Therapeutics plc [NASDAQ: ITRM] price surged by 7.93 percent to reach at $0.13. The company report on February 20, 2021 that Iterum Therapeutics to Present in Upcoming Investor Conferences.
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that Corey Fishman, Chief Executive Officer, will provide a company overview and business update at the following upcoming investor conferences:.
SVB Leerink Annual Global Healthcare Conference: Thursday, February 25, 2021 at 3:00 pm ET.
A sum of 12543348 shares traded at recent session while its average daily volume was at 23.41M shares. Iterum Therapeutics plc shares reached a high of $1.85 and dropped to a low of $1.68 until finishing in the latest session at $1.77.
The one-year ITRM stock forecast points to a potential downside of -18.0. The average equity rating for ITRM stock is currently 3.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Iterum Therapeutics plc [ITRM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ITRM shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ITRM stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Iterum Therapeutics plc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on June 02, 2020. The new note on the price target was released on January 21, 2020, representing the official price target for Iterum Therapeutics plc stock.
The Average True Range (ATR) for Iterum Therapeutics plc is set at 0.32
ITRM Stock Performance Analysis:
Iterum Therapeutics plc [ITRM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.81. With this latest performance, ITRM shares gained by 23.78% in over the last four-week period, additionally plugging by 139.19% over the last 6 months – not to mention a drop of -26.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITRM stock in for the last two-week period is set at 50.10, with the RSI for the last a single of trading hit 46.21, and the three-weeks RSI is set at 52.42 for Iterum Therapeutics plc [ITRM]. The present Moving Average for the last 50 days of trading for this stock 1.4819, while it was recorded at 1.7880 for the last single week of trading, and 1.2358 for the last 200 days.
Insight into Iterum Therapeutics plc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Iterum Therapeutics plc [ITRM] shares currently have an operating margin of -275732.43. Iterum Therapeutics plc’s Net Margin is presently recorded at -278729.73.
Return on Total Capital for ITRM is now -254.31, given the latest momentum, and Return on Invested Capital for the company is -283.18. Return on Equity for this stock declined to -454.48, with Return on Assets sitting at -166.85.
Reflecting on the efficiency of the workforce at the company, Iterum Therapeutics plc [ITRM] managed to generate an average of -$2,343,864 per employee. Receivables Turnover for the company is 0.04 with a Total Asset Turnover recorded at a value of 0.00.Iterum Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
ITRM Stock EPS
With the latest financial reports released by the company, Iterum Therapeutics plc posted -1.59/share EPS, while the average EPS was predicted by analysts to be reported at -1.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ITRM.
Iterum Therapeutics plc [ITRM] Insider Position Details
There are presently around $12 million, or 12.00% of ITRM stock, in the hands of institutional investors. The top three institutional holders of ITRM stocks are: CANAAN PARTNERS X LLC with ownership of 1,733,170, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 1,538,316 shares of the stock with an approximate value of $2.72 million in ITRM stocks shares; and NEW LEAF VENTURE PARTNERS, L.L.C., currently with $2.58 million in ITRM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Iterum Therapeutics plc stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 13 institutional holders increased their position in Iterum Therapeutics plc [NASDAQ:ITRM] by around 2,154,948 shares. Additionally, 5 investors decreased positions by around 146,007 shares, while 6 investors held positions by with 4,682,869 shares. The mentioned changes placed institutional holdings at 6,983,824 shares, according to the latest SEC report filing. ITRM stock had 12 new institutional investments in for a total of 2,005,968 shares, while 5 institutional investors sold positions of 146,007 shares during the same period.